{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:58:09Z","timestamp":1772927889732,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology","doi-asserted-by":"publisher","award":["JBR\/2021\/ 000010"],"award-info":[{"award-number":["JBR\/2021\/ 000010"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.molimm.2025.04.014","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:30:27Z","timestamp":1746815427000},"page":"104-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunotherapeutic efficacy of Th1 stimulatory epitopes derived from Leishmania donovani enolase and triose phosphatase isomerase in experimental visceral leishmaniasis"],"prefix":"10.1016","volume":"183","author":[{"given":"Sneha","family":"Ratnapriya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok K.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-0734","authenticated-orcid":false,"given":"Amogh Anant","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2025.04.014_bib1","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.molimm.2025.04.014_bib2","first-page":"00268","article-title":"Experimental validation of multi-epitope peptides including promising MHC class I- and II-restricted epitopes of four known Leishmania infantum proteins","volume":"2014","author":"Agallou","year":"2014","journal-title":"Front. Immunol. fimmu"},{"key":"10.1016\/j.molimm.2025.04.014_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.vetimm.2008.11.020","article-title":"Expression of IFN-\u03b3, TNF-\u03b1, IL-10 and TGF-\u03b2 in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi","volume":"128","author":"Alves","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.molimm.2025.04.014_bib4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/infdis\/173.6.1515","article-title":"Interleukin-12 restores interferon-\u03b3 production and cytotoxic responses in visceral leishmaniasis","volume":"173","author":"Bacellar","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.molimm.2025.04.014_bib6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/21645515.2015.1119346","article-title":"A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB\/c mouse model of Chagas disease","volume":"12","author":"Barry","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.molimm.2025.04.014_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib8","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3389\/fmicb.2016.01536","article-title":"The progress of therapeutic vaccination with regard to tuberculosis","volume":"7","author":"Cardona","year":"2016","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.molimm.2025.04.014_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.molimm.2025.04.014_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multiantigen T cell epitope\u2013enriched DNA vaccine against human leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.molimm.2025.04.014_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00436-005-1339-1","article-title":"Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models","volume":"96","author":"Dube","year":"2005","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.molimm.2025.04.014_bib13","first-page":"2","article-title":"A defined subunit vaccine that protects against vector-borne visceral leishmaniasis","volume":"21","author":"Duthie","year":"2017","journal-title":"N. P. J. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.014_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/trstmh\/trv039","article-title":"Development of Leishmania vaccines in the era of visceral leishmaniasis elimination","volume":"109","author":"Engwerda","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.molimm.2025.04.014_bib15","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1016\/j.vaccine.2015.06.117","article-title":"New approaches to understanding the immune response to vaccination and infection","volume":"33","author":"Furman","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2249.2005.02745.x","article-title":"Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani","volume":"140","author":"Garg","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib17","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.vaccine.2005.12.053","article-title":"Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis","volume":"24","author":"Garg","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.4049\/jimmunol.148.6.1792","article-title":"IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages","volume":"148","author":"Gazzinelli","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib19","first-page":"4623","article-title":"IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. (Baltimore","author":"Ghalib","year":"1995","journal-title":"Md 1950) 154"},{"key":"10.1016\/j.molimm.2025.04.014_bib20","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib21","first-page":"286","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven","year":"2014","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/pmic.200600725","article-title":"Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes","volume":"7","author":"Gupta","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.molimm.2025.04.014_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fmicb.2016.00312","article-title":"Comparative analysis of cellular immune responses in treated Leishmania patients and hamsters against recombinant Th1 stimulatory proteins of Leishmania donovani","volume":"7","author":"Joshi","year":"2016","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.molimm.2025.04.014_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fimmu.2019.00288","article-title":"Immunogenicity and protective efficacy of T-cell epitopes derived from potential Th1 stimulatory proteins of Leishmania (Leishmania) donovani","volume":"10","author":"Joshi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14712598.2014.945415","article-title":"Therapeutic vaccines for leishmaniasis","volume":"14","author":"Khamesipour","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molimm.2025.04.014_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1473-3099(05)70085-2","article-title":"Recombinant DNA-derived leishmania proteins: from the laboratory to the field","volume":"5","author":"Kubar","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib27","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1016\/j.vaccine.2008.08.021","article-title":"Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib28","first-page":"2014","article-title":"Innate immunity to Leishmania infection: within phagocytes","author":"Lopes","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.molimm.2025.04.014_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.molimm.2025.04.014_bib30","article-title":"Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B. Can. J. Infect. Dis. Med. Microbiol","author":"McQuarrie","year":"2015","journal-title":"=\u2009J. Can. Des. Mal. Infect. la Microbiol. Med."},{"key":"10.1016\/j.molimm.2025.04.014_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molimm.2025.04.014_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"Morrow","year":"2013","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.014_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for Leishmania vaccine candidates","volume":"24","author":"Mutiso","year":"2010","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.molimm.2025.04.014_bib34","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/jid.2012.315","article-title":"Delayed-type hypersensitivity to sand fly saliva in humans from a leishmaniasis-endemic area of Mali is Th1-mediated and persists to midlife","volume":"133","author":"Oliveira","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molimm.2025.04.014_bib36","doi-asserted-by":"crossref","unstructured":"Onile, O.S., Musaigwa, F., Ayawei, N., Omoboyede, V., Onile, T.A., Oghenevovwero, E., Aruleba, R.T., 2022. Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis.","DOI":"10.3390\/vaccines10101598"},{"key":"10.1016\/j.molimm.2025.04.014_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0144-2","article-title":"Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis","volume":"4","author":"Petitdidier","year":"2019","journal-title":"npj Vaccin."},{"key":"10.1016\/j.molimm.2025.04.014_bib38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molimm.2025.04.014_bib39","article-title":"Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India","volume":"9","author":"Ramesh","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/VDT.S110654","article-title":"Management of visceral leishmaniasis with therapeutic vaccines","volume":"6","author":"Rawat","year":"2016","journal-title":"Vaccin. Dev. Ther."},{"key":"10.1016\/j.molimm.2025.04.014_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pt.2010.04.005","article-title":"Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis","volume":"26","author":"Reis","year":"2010","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.molimm.2025.04.014_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: Promising treatments for this neglected disease","author":"Roatt","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2017.00217","article-title":"A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden","volume":"8","author":"Roatt","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.molimm.2025.04.014_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2567.2006.02391.x","article-title":"Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen","volume":"118","author":"Saha","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.molimm.2025.04.014_bib47","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.014_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0001-706X(00)00068-1","article-title":"Leishmania donovani in blood smears of asymptomatic persons","volume":"76","author":"Sharma","year":"2000","journal-title":"Acta Trop."},{"key":"10.1016\/j.molimm.2025.04.014_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2014.00296","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"5","author":"Singh","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2025.04.014_bib50","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/cid\/ciu102","article-title":"Asymptomatic Leishmania infection: a new challenge for Leishmania control","volume":"58","author":"Singh","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.014_bib51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.icb7100011","article-title":"Balancing immunity and pathology in visceral leishmaniasis","volume":"85","author":"Stanley","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.molimm.2025.04.014_bib52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S003118201600216X","article-title":"Leishmaniasis and various immunotherapeutic approaches","volume":"145","author":"Taslimi","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.molimm.2025.04.014_bib53","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1586\/erv.09.109","article-title":"Towards improved understanding of protective mechanisms induced by the BCG vaccine","volume":"8","author":"Villarreal-Ramos","year":"2009","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.014_bib54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.molimm.2025.04.014_bib55","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.micinf.2004.05.024","article-title":"Requirements for Th1-dependent immunity against infection with Leishmania major","volume":"6","author":"Von Stebut","year":"2004","journal-title":"Microbes Infect."},{"key":"10.1016\/j.molimm.2025.04.014_bib56","unstructured":"WHO, 2019. No Title. \u201cLeishmaniasis,\u201d http:\/\/www."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:13:54Z","timestamp":1749269634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589025001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"alternative-id":["S0161589025001117"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2025.04.014","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic efficacy of Th1 stimulatory epitopes derived from Leishmania donovani enolase and triose phosphatase isomerase in experimental visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2025.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}